Business Wire

Outpost24 Appoints Martin Roth as Chief Technology Officer to Advance Global Engineering and Innovation

9.10.2025 13:00:00 CEST | Business Wire | Press Release

Share

Outpost24, a leader in exposure management and identity security, today announced the appointment of Martin Roth as Chief Technology Officer (CTO). Martin brings over 25 years of experience in software development, with a proven record of building and transforming technology organizations. His background combines deep technical expertise in product innovation and enterprise solution delivery with the ability to lead large, distributed teams in complex, security-sensitive environments.

Before joining Outpost24, Martin held pivotal leadership roles at groundbreaking companies, such as Learnster, Viaplay, and Snow Software (now part of Flexera). In these roles, he was instrumental in scaling global Research & Development organizations through periods of rapid growth, establishing modern engineering and DevOps practices, and driving initiatives that dramatically strengthened delivery, innovation, and security across large enterprise software platforms.

At Outpost24, Martin will lead the company’s global engineering and technology strategy, shaping architecture, delivery, and development practices to drive agility and performance. Under his leadership, the company will accelerate its transition to cloud-native technologies, focusing on AI-driven solutions that will help its customers improve operational efficiency and their cybersecurity posture. He will drive a unified technical vision to enhance the delivery of the full-stack security platform—spanning continuous threat exposure management (CTEM), digital risk protection, cyber threat intelligence, and compliance—by building scalable systems and empowered teams that enable the company to innovate quickly and securely.

The appointment comes at a critical time for the cybersecurity industry, where proactive defence and a shift-left security approach are paramount. As threats become more sophisticated and regulatory pressures intensify, Outpost24 recognizes that world-class engineering is the foundation for delivering trusted, scalable security solutions. Martin’s expertise in building robust, high-availability enterprise platforms will be immediately leveraged to meet these escalating market demands.

“We are thrilled to welcome Martin to Outpost24,” said Ido Erlichman, CEO of Outpost24. “His proven experience leading global engineering teams, modernizing technology organizations, and driving operational excellence will be invaluable as we continue to scale our platform and deliver greater value to our customers worldwide.”

“Outpost24 has a strong technical foundation and a clear vision for the future,” said Martin Roth, new CTO of Outpost24. “I look forward to advancing our engineering organization and ensuring Outpost24 remains at the forefront of technology and innovation.”

Martin’s appointment follows recent additions to Outpost24’s leadership team, including a new Chief Information Security Officer (CISO) and Chief Corporate Development Officer (CCDO) — reinforcing the company’s commitment to innovation, technical excellence, and global expansion.

With a strong European presence and thousands of customers worldwide, Outpost24 continues to build the technological backbone for modern Exposure Management and Continuous Threat Exposure Management (CTEM), helping organizations proactively identify, prioritize, and remediate cyber risks across both digital and human attack surfaces.

About Outpost24

Outpost24 is a leading provider of exposure management and identity security solutions. By combining its core Attack Surface Management platform with the identity and password security expertise of Specops, the company helps thousands of organizations worldwide proactively identify, manage, and reduce cyber risk across their entire digital and human attack surfaces. Founded in 2001 and headquartered in Sweden, Outpost24 has 12 additional offices globally, including in the US, UK, France, Belgium, and Spain. For more information, visit https://outpost24.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251009999214/en/

Contacts

Media Contact:
Tila Pacheco
Eskenzi PR
tila@eskenzipr.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye